Benz, Matthias R.;
Czernin, Johannes;
Tap, William D.;
Eckardt, Jeffrey J.;
Seeger, Leanne L.;
Allen-Auerbach, Martin S.;
Dry, Sarah M.;
Phelps, Michael E.;
Weber, Wolfgang A.;
Eilber, Fritz C.
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas
Beteiligte:
Benz, Matthias R.;
Czernin, Johannes;
Tap, William D.;
Eckardt, Jeffrey J.;
Seeger, Leanne L.;
Allen-Auerbach, Martin S.;
Dry, Sarah M.;
Phelps, Michael E.;
Weber, Wolfgang A.;
Eilber, Fritz C.
Beschreibung:
<jats:p><jats:italic>Purpose</jats:italic>. The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas.<jats:italic>Methods</jats:italic>. Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response.<jats:italic>Results</jats:italic>. Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mn>64</mml:mn><mml:mo>±</mml:mo><mml:mn>19</mml:mn></mml:mrow></mml:math>% versus<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mn>29</mml:mn><mml:mo>±</mml:mo><mml:mn>30</mml:mn></mml:math>%, resp.;<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.03</mml:mn></mml:math>). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%).<jats:italic>Conclusion</jats:italic>. These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients.</jats:p>